CERENO SCIENTIFIC AB B (F:4A1) — Market Cap & Net Worth
Market Cap & Net Worth: CERENO SCIENTIFIC AB B (4A1)
CERENO SCIENTIFIC AB B (F:4A1) has a market capitalization of $123.09 Million (€105.28 Million) as of September 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #18475 globally and #1712 in its home market, demonstrating a 5.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CERENO SCIENTIFIC AB B's stock price €0.39 by its total outstanding shares 311365076 (311.37 Million). Also see 4A1 asset base for a full breakdown of the balance sheet.
CERENO SCIENTIFIC AB B Market Cap History: 2021 to 2026
CERENO SCIENTIFIC AB B's market capitalization history from 2021 to 2026. Data shows growth from $169.45 Million to $141.09 Million (5.98% CAGR). Also see cash flow conversion of CERENO SCIENTIFIC AB B for how efficiently the company converts equity into cash flow.
CERENO SCIENTIFIC AB B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CERENO SCIENTIFIC AB B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for CERENO SCIENTIFIC AB B for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4A1 by Market Capitalization
Companies near CERENO SCIENTIFIC AB B in the global market cap rankings as of September 17, 2026. Review 4A1 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CERENO SCIENTIFIC AB B by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
CERENO SCIENTIFIC AB B Historical Marketcap From 2021 to 2026
Between 2021 and today, CERENO SCIENTIFIC AB B's market cap moved from $169.45 Million to $ 141.09 Million, with a yearly change of 5.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €141.09 Million | -38.96% |
| 2025 | €231.15 Million | +38.53% |
| 2024 | €166.87 Million | +3.01% |
| 2023 | €161.99 Million | +154.87% |
| 2022 | €63.56 Million | -62.49% |
| 2021 | €169.45 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of CERENO SCIENTIFIC AB B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.09 Million USD |
| MoneyControl | $123.09 Million USD |
| MarketWatch | $123.09 Million USD |
| marketcap.company | $123.09 Million USD |
| Reuters | $123.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as a… Read more